We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serum Magnesium Levels Associated with CAP Mortality

By LabMedica International staff writers
Posted on 07 Jan 2019
Image: The Dimension EXL 200 integrated chemistry system (Photo courtesy of Siemens Healthcare).
Image: The Dimension EXL 200 integrated chemistry system (Photo courtesy of Siemens Healthcare).
Community acquired pneumonia (CAP) is a common illness affecting hundreds of millions worldwide, with increasing hospital admissions throughout the years mainly due to the aging population. It is a major cause of mortality and morbidity in all age groups, especially the elderly.

Magnesium deficiency has been associated with a number of clinical manifestations such as arrhythmias, cardiac insufficiency, sudden death, muscle weakness, bronchospasm, tetany, seizures, as well as hypokalemia, hypocalcaemia, hyponatremia, and hypophosphatemia. Hypermagnesemia may cause severe symptomatic hypotension, bradycardia and ECG changes like wide QRS.

Scientists at the Rambam Health Care Campus (Haifa, Israel) and their colleagues retrospectively reviewed between January 1, 2010, and December 31, 2016, the data of 4,708 patients diagnosed with CAP at discharge; 3,851 patients had magnesium levels within 48 hours, and 55% were males and the median age was 72 years old. Participants were analyzed retrospectively in order to identify the risk factors for a primary endpoint of 30-day mortality.

The Charlson’s comorbidity score was calculated based on data collected; laboratory values (first values within 48 hours): Hemoglobin (Hb), White blood cell count (WBC), red blood cell distribution width (RDW), pH, partial pressure of carbon dioxide (pCO2), serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin. Hematological values were measured using the Advia 120 Hematology Analyzer. Serum glucose, serum creatinine, sodium, calcium, phosphorus, magnesium, blood urea nitrogen (BUN), and serum albumin were measured on admission using Siemens’ Dimension Integrated Chemistry System; PH, bicarbonate, partial pressure of CO2 and lactate were measured using GEM premier 3500.

The team reported that blood urea nitrogen (BUN) > 20 mg/dL, hypoalbuminemia, and abnormal levels of magnesium were all associated with increased risk of 30-day mortality. Normal magnesium levels were associated with the lowest mortality rate (14.7%). Notably, within the normal levels, high normal magnesium levels (2.0 to 2.4 mg/dL) were correlated with higher mortality rates (30.3%) as compared to levels that ranged between 1.35 to 2 mg/dL (12.9%). Hypomagnesemia and hypermagnesemia were both associated with excess of 30-day mortality, 18.4 and 50%, respectively. Normal levels of magnesium levels in their laboratory vary between 1.35 and 2.4 mg/dL.

The authors concluded that hypomagnesemia and hypermagnesemia on admission were associated with an increased rate of 30-day mortality among adult patients hospitalized with CAP. Interestingly, magnesium levels within the upper normal limits were associated with higher mortality. The study was published on December 27, 2018, in the journal BMC Infectious Diseases.

Related Links:
Rambam Health Care Campus

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Chemistry Analyzer
Yumizen C600
New
Bacterial GI Multiplex PCR Assay
Allplex GI-Bacteria(I) plus Assay

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
INTEGRA BIOSCIENCES AG